Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Artemether-lumefantrine on Auditory Function in Malaria
NCT00444106Phase 4Completed
- Sponsor
- Novartis
- Start
- May 2007
- Primary completion
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of artemether + lumefantrine in Plasmodium falciparum malaria (3 arms), sponsored by Novartis. Primary endpoint: Percentage of Participants With Auditory Abnormalities at Day 7 Assessed by Auditory Brainstem Response (ABR) Wave III Latency Changes. Started May 2007; status: completed.
02
Drugs
artemether + lumefantrine
03
Conditions
Plasmodium falciparum malaria
Beyond the preview
Go deeper on NCT00444106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00444106.